Compare Neurocrine Biosciences Inc (NBIX) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Palo Alto Networks Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Palo Alto Networks Inc trades at $336.16 (market cap $274.64B). The key difference: Palo Alto Networks Inc is far larger — about 17.4× Neurocrine Biosciences Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PANW | |
|---|---|---|
Market Cap | $15.77B | $274.64B |
Sector | Health | Technology |
52-Week High | $185.50 | $396.00 |
52-Week Low | $123.10 | $141.67 |
Enterprise Value | $15.78B | $273.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Palo Alto Networks (PANW) trades at $336.98, up 1.12% with a bearish technical signal but strong fundamentals. Revenue grew to $9.22B in 2025, with EPS beats in recent quarters. The stock faces high valuation multiples (P/E 293.03) and mixed sentiment amid AI-driven growth and recent price volatility.
Outlook: Growth is supported by AI security demand and platformization strategy, but risks include premium valuation and competitive pressures. Analyst consensus is bullish with a $410.48 price target, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
